Evidence map›Paper›PMID 29859965›Full record

ArticleThe Journal of allergy and clinical immunology2019

Autoantibodies to IgE and FcεRI and the natural variability of spleen tyrosine kinase expression in basophils.

Donald MacGlashan

Abstract read
In one paragraph

Article in The Journal of allergy and clinical immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
4.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.

  1. Comparative efficacy and safety of the treatment by Omalizumab for chronic idiopathic urticaria in the general population: A systematic review and network meta-analysis.Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) · 2024
    Pooled it
  2. Review
  3. Chronic Spontaneous Urticaria: Etiology and Pathogenesis.Immunology and allergy clinics of North America · 2024
    Review
  4. Review
  5. Article
  6. Article
  7. Association of a SYK promoter polymorphism with SYK expression and IgE-mediated histamine release.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2023
    Article
  8. Ozonated oil alleviates dinitrochlorobenzene-induced allergic contact dermatitis via inhibiting the FcεRI/Syk signaling pathway.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2023
    Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Current and emerging treatments for chronic spontaneous urticaria.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2020
    Review
  17. Article
  18. Article
  19. Advances in drug allergy, urticaria, angioedema, and anaphylaxis in 2018.The Journal of allergy and clinical immunology · 2019
    Review
  20. Emerging Therapies in Chronic Spontaneous Urticaria.Allergy, asthma & immunology research · 2019
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Donald MacGlashanAsthma and Allergy Center, Johns Hopkins University, Baltimore, Md. Electronic address: dmacglas@jhmi.edu.
Johns Hopkins University · US

Funding

The Role of CD32 in the Basophil Response to Specific ImmunotherapyU01AI100952 · NIAID · JOHNS HOPKINS UNIVERSITY · PI MACGLASHAN, DONALD W · 2014 to 2018
$2.0M
Role of IgE Bearing Cells in Chronic Idiopathic UrticariaR01AI116658 · NIAID · JOHNS HOPKINS UNIVERSITY · PI SAINI, SARBJIT SINGH · 2016 to 2018
$1.4M
The Role of CD32 in the Basophil Response to Specific ImmunotherapyR56AI100952 · NIAID · JOHNS HOPKINS UNIVERSITY · PI MACGLASHAN, DONALD W · 2012 to 2012
$324k
NIAID NIH HHS R01 AI116658NIAID NIH HHS R56 AI100952NIAID NIH HHS U01 AI100952
6 · The paper itself

Abstract

backgroundSecretion from human basophils and mast cells requires spleen tyrosine kinase (SYK) activity, but SYK expression is highly variable in the general population, and this variability predicts the magnitude of IgE-mediated secretion. One known mechanism of modulating SYK expression in human basophils is aggregation of FcεRI.

objectiveThis study examines the possibility that functional autoantibodies are present in a wide variety of subjects and, in particular, subjects whose basophils poorly express SYK. It also tests whether any found antibodies could modulate SYK expression in maturing basophils and whether interaction with FcγRIIb/CD32b modulates the effect.

methodsAn experimental algorithm for classifying the nature of histamine release induced by serum from 3 classes of subjects was developed.

resultsThe frequency of functional autoantibodies that produce characteristics concordant with FcεRI-mediated secretion was zero in 34 subjects without chronic spontaneous urticaria (CSU). In patients with CSU, the frequency was lower than expected, approximately 7%. For the 5 of 68 unique sera from patients with CSU tested that contained anti-FcεRI or anti-IgE antibodies, these antibodies were found to induce downregulation of SYK in both peripheral blood basophils and basophils developed from CD34

conclusionsThis study establishes that functional autoantibodies to IgE/FcεRI do not provide a good explanation for the variability in SYK expression in basophils in the general population. They do show that if antibodies with these characteristics are present, they are capable of modulating SYK expression in developing basophils.

Indexed as

AutoantibodiesBasophilsCells, CulturedChronic DiseaseHumansImmunoglobulin EReceptors, IgESyk KinaseUrticariaAutoantibodiesImmunoglobulin EReceptors, IgESyk KinaseSYK protein, humanallergybasophilFc receptorsHuman

Identifiers

PMID29859965
PMCPMC6274596
OpenAlexW2805213648

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.